Candesartan effect on inflammation in hypertension

Giuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Ilaria Palumbo, Angela D'Angelo, Arrigo F G Cicero

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of candesartan on inflammatory biomarkers in hypertensive patients with and without type 2 diabetes mellitus after a standardized oral fat load (OFL). A total of 219 patients were enrolled: 106 patients were assigned to the non-diabetic hypertensive (NH) group, and 113 to the diabetic hypertensive (DH) group. All patients received candesartan therapy for 6 months and underwent a standardized OFL at baseline and after 6 months of therapy. We evaluated systolic blood pressure (SBP) and diastolic blood pressure (DBP), blood glucose (BG), triglycerides (Tg), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and high-sensitivity C reactive protein (Hs-CRP). At baseline, glycated hemoglobin, homeostasis model assessment insulin resistance index, BG, fasting plasma insulin, Tg, sICAM-1, IL-6 and Hs-CRP in the DH group were significantly higher, whereas high-density lipoprotein-cholesterol value was significantly lower compared to NH group. After 6 months of candesartan therapy, sICAM-1, IL-6 and Hs-CRP were significantly lower compared to baseline in both groups; furthermore, there was a significant decrease of SBP and DBP values in both groups. After the OFL administered at baseline, there was an increase of Tg, sICAM-1, IL-6 and Hs-CRP in both groups. After the OFL administered after 6 months of therapy, instead, there was no significant variation of BG, Tg or sICAM-1 value in both groups, whereas there was an increase of IL-6 and Hs-CRP compared to time 0. We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones.

Original languageEnglish
Pages (from-to)209-213
Number of pages5
JournalHypertension Research
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Blood Pressure
Hypertension
Inflammation
Intercellular Adhesion Molecule-1
C-Reactive Protein
Interleukin-6
Triglycerides
Fats
Blood Glucose
Therapeutics
candesartan
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
HDL Cholesterol
Insulin Resistance
Fasting
Homeostasis
Biomarkers
Insulin

Keywords

  • Candesartan
  • Inflammation
  • Oral fat load
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Candesartan effect on inflammation in hypertension. / Derosa, Giuseppe; Maffioli, Pamela; Salvadeo, Sibilla A T; Ferrari, Ilaria; Gravina, Alessia; Mereu, Roberto; Palumbo, Ilaria; D'Angelo, Angela; Cicero, Arrigo F G.

In: Hypertension Research, Vol. 33, No. 3, 03.2010, p. 209-213.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Maffioli, Pamela ; Salvadeo, Sibilla A T ; Ferrari, Ilaria ; Gravina, Alessia ; Mereu, Roberto ; Palumbo, Ilaria ; D'Angelo, Angela ; Cicero, Arrigo F G. / Candesartan effect on inflammation in hypertension. In: Hypertension Research. 2010 ; Vol. 33, No. 3. pp. 209-213.
@article{5e7da63a000346688a2dc10d9cefc6b1,
title = "Candesartan effect on inflammation in hypertension",
abstract = "The aim of this study was to evaluate the effect of candesartan on inflammatory biomarkers in hypertensive patients with and without type 2 diabetes mellitus after a standardized oral fat load (OFL). A total of 219 patients were enrolled: 106 patients were assigned to the non-diabetic hypertensive (NH) group, and 113 to the diabetic hypertensive (DH) group. All patients received candesartan therapy for 6 months and underwent a standardized OFL at baseline and after 6 months of therapy. We evaluated systolic blood pressure (SBP) and diastolic blood pressure (DBP), blood glucose (BG), triglycerides (Tg), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and high-sensitivity C reactive protein (Hs-CRP). At baseline, glycated hemoglobin, homeostasis model assessment insulin resistance index, BG, fasting plasma insulin, Tg, sICAM-1, IL-6 and Hs-CRP in the DH group were significantly higher, whereas high-density lipoprotein-cholesterol value was significantly lower compared to NH group. After 6 months of candesartan therapy, sICAM-1, IL-6 and Hs-CRP were significantly lower compared to baseline in both groups; furthermore, there was a significant decrease of SBP and DBP values in both groups. After the OFL administered at baseline, there was an increase of Tg, sICAM-1, IL-6 and Hs-CRP in both groups. After the OFL administered after 6 months of therapy, instead, there was no significant variation of BG, Tg or sICAM-1 value in both groups, whereas there was an increase of IL-6 and Hs-CRP compared to time 0. We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones.",
keywords = "Candesartan, Inflammation, Oral fat load, Type 2 diabetes mellitus",
author = "Giuseppe Derosa and Pamela Maffioli and Salvadeo, {Sibilla A T} and Ilaria Ferrari and Alessia Gravina and Roberto Mereu and Ilaria Palumbo and Angela D'Angelo and Cicero, {Arrigo F G}",
year = "2010",
month = "3",
doi = "10.1038/hr.2009.212",
language = "English",
volume = "33",
pages = "209--213",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Candesartan effect on inflammation in hypertension

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - Salvadeo, Sibilla A T

AU - Ferrari, Ilaria

AU - Gravina, Alessia

AU - Mereu, Roberto

AU - Palumbo, Ilaria

AU - D'Angelo, Angela

AU - Cicero, Arrigo F G

PY - 2010/3

Y1 - 2010/3

N2 - The aim of this study was to evaluate the effect of candesartan on inflammatory biomarkers in hypertensive patients with and without type 2 diabetes mellitus after a standardized oral fat load (OFL). A total of 219 patients were enrolled: 106 patients were assigned to the non-diabetic hypertensive (NH) group, and 113 to the diabetic hypertensive (DH) group. All patients received candesartan therapy for 6 months and underwent a standardized OFL at baseline and after 6 months of therapy. We evaluated systolic blood pressure (SBP) and diastolic blood pressure (DBP), blood glucose (BG), triglycerides (Tg), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and high-sensitivity C reactive protein (Hs-CRP). At baseline, glycated hemoglobin, homeostasis model assessment insulin resistance index, BG, fasting plasma insulin, Tg, sICAM-1, IL-6 and Hs-CRP in the DH group were significantly higher, whereas high-density lipoprotein-cholesterol value was significantly lower compared to NH group. After 6 months of candesartan therapy, sICAM-1, IL-6 and Hs-CRP were significantly lower compared to baseline in both groups; furthermore, there was a significant decrease of SBP and DBP values in both groups. After the OFL administered at baseline, there was an increase of Tg, sICAM-1, IL-6 and Hs-CRP in both groups. After the OFL administered after 6 months of therapy, instead, there was no significant variation of BG, Tg or sICAM-1 value in both groups, whereas there was an increase of IL-6 and Hs-CRP compared to time 0. We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones.

AB - The aim of this study was to evaluate the effect of candesartan on inflammatory biomarkers in hypertensive patients with and without type 2 diabetes mellitus after a standardized oral fat load (OFL). A total of 219 patients were enrolled: 106 patients were assigned to the non-diabetic hypertensive (NH) group, and 113 to the diabetic hypertensive (DH) group. All patients received candesartan therapy for 6 months and underwent a standardized OFL at baseline and after 6 months of therapy. We evaluated systolic blood pressure (SBP) and diastolic blood pressure (DBP), blood glucose (BG), triglycerides (Tg), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and high-sensitivity C reactive protein (Hs-CRP). At baseline, glycated hemoglobin, homeostasis model assessment insulin resistance index, BG, fasting plasma insulin, Tg, sICAM-1, IL-6 and Hs-CRP in the DH group were significantly higher, whereas high-density lipoprotein-cholesterol value was significantly lower compared to NH group. After 6 months of candesartan therapy, sICAM-1, IL-6 and Hs-CRP were significantly lower compared to baseline in both groups; furthermore, there was a significant decrease of SBP and DBP values in both groups. After the OFL administered at baseline, there was an increase of Tg, sICAM-1, IL-6 and Hs-CRP in both groups. After the OFL administered after 6 months of therapy, instead, there was no significant variation of BG, Tg or sICAM-1 value in both groups, whereas there was an increase of IL-6 and Hs-CRP compared to time 0. We observed that candesartan treatment attenuated the inflammatory answer in both groups of patients, even if more efficiently in nondiabetic ones.

KW - Candesartan

KW - Inflammation

KW - Oral fat load

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=77749246297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749246297&partnerID=8YFLogxK

U2 - 10.1038/hr.2009.212

DO - 10.1038/hr.2009.212

M3 - Article

C2 - 20075928

AN - SCOPUS:77749246297

VL - 33

SP - 209

EP - 213

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 3

ER -